What the *trials* actually show

What this page covers

This page summarizes the published clinical research on retatrutide from the molecular discovery work through the first Phase 3 readout. It is organized by study — mechanism first, then Phase 1b pharmacokinetics, then the Phase 2 obesity and type 2 diabetes trials, then the liver-fat substudy, then the ongoing TRIUMPH Phase 3 program. Every number is cited to the primary source. The research record shows a consistent direction across studies: large weight-loss effect sizes, meaningful glycemic improvement in type 2 diabetes, and striking liver-fat reductions in participants with MASLD. What the record does not yet show is long-term cardiovascular safety or durability after stopping — both are open questions the Phase 3 program is designed to answer. If you want the plain-English account of what people report and what to watch for, that is on the effects page. If you want the full citation list with DOIs, that is on references.

Mechanism: three receptors, one peptide

Retatrutide is described in the medicinal-chemistry literature as a 'tri-agonist' — a single peptide engineered to activate the GIP, GLP-1, and glucagon receptors with deliberately tuned relative potencies. Coskun and colleagues, in the 2022 Cell Metabolism discovery paper, reported relative receptor activities of roughly 8.9-fold over native GIP at GIPR, 0.3× glucagon at GCGR, and 0.4× GLP-1 at GLP-1R ^[6]. The imbalance is intentional. Higher GIPR engagement supports insulin secretion and appears to soften the nausea profile at higher doses; moderate GCGR engagement adds an energy-expenditure and hepatic-lipid-oxidation contribution without overwhelming the insulin-secretory drive of the other two arms.

In 2024, cryo-electron microscopy structures of retatrutide bound to each of the three receptor-Gs complexes were resolved at 2.68, 3.26, and 2.84 Å ^[7]. The structures revealed receptor-specific conformations of extracellular loop 1 (ECL1) that explain how a single peptide can satisfy three different binding pockets. For the working clinician or curious reader, the practical takeaway is that the polypharmacology is not a happy accident but a designed property — and that the same structural insights are now informing the next generation of tri- and tetra-agonists.

Mechanistically, GLP-1R activation drives glucose-dependent insulin secretion, slowed gastric emptying, and central satiety signaling through POMC neurons in the arcuate nucleus. GIPR activation amplifies insulin release and modulates CNS appetite circuits. GCGR activation raises basal energy expenditure and accelerates hepatic fat oxidation — and is the principal reason the liver-fat reductions in the MASLD substudy are larger than what GLP-1 or GLP-1/GIP agonists have produced.

Phase 1b: dose-finding in type 2 diabetes

The first multiple-ascending-dose trial in humans was reported by Urva and colleagues in The Lancet in 2022 ^[5]. Adults with type 2 diabetes received escalating weekly doses from 0.5 mg up to 12 mg over 12 weeks. The plasma half-life landed at roughly 6 days, dose-proportional pharmacokinetics held across the studied range, and the trial established the once-weekly subcutaneous schedule that all subsequent retatrutide trials have used. HbA1c reductions reached 1.9 percentage points and weight loss reached 8.9 kg at the top dose. Gastrointestinal events — nausea, vomiting, diarrhea — were the dominant adverse-event class, concentrated in the dose-escalation period.

Phase 2 obesity (NEJM 2023)

The Jastreboff Phase 2 obesity trial randomized adults with BMI ≥30 (or ≥27 with a weight-related comorbidity) and without type 2 diabetes to 1, 4, 8, or 12 mg retatrutide weekly or placebo, with stepwise dose escalation ^[1]. At 48 weeks the least-squares mean weight change in the 12 mg arm was -24.2% versus -2.1% on placebo. The interim 24-week analysis showed -7.2% (1 mg), -12.9% (4 mg), -17.3% (8 mg), and -17.5% (12 mg) versus -1.6% on placebo — a dose-response that the authors noted had not plateaued at 24 weeks at any dose ^[2].

Nausea was the most common adverse event, reported in 36% of participants on the 1 mg arm and 59% on the 12 mg arm. Vomiting ranged from 8% to 39%. Most gastrointestinal events were mild to moderate and clustered in the first 16 weeks of titration. Treatment-discontinuation rates ranged from 6% to 16% across the dose cohorts ^[9]. Resting heart rate rose dose-dependently to a peak of roughly +6.7 bpm at the 12 mg dose at 24 weeks, then drifted back toward baseline through weeks 36–48 — a transient pattern broadly similar to that observed with other GLP-1 receptor agonists ^[10].

Phase 2 type 2 diabetes (Lancet 2023)

Rosenstock and colleagues reported the parallel Phase 2 trial in adults with type 2 diabetes (baseline HbA1c 7.0–10.5%) randomized to 0.5, 4, 8, or 12 mg retatrutide weekly, dulaglutide 1.5 mg, or placebo ^[3]. At 24 weeks the 12 mg arm reduced HbA1c by approximately 2.0 percentage points and body weight by about 16.9%. Up to 82% of participants on retatrutide achieved an HbA1c below 6.5% — a threshold often used as a stand-in for diabetes remission in trial reports. A 2025 pre-specified body-composition substudy reported substantial reductions in total fat mass with relatively preserved lean mass at higher doses, partly answering the standing question about whether glucagon-receptor agonism would compromise lean tissue ^[14].

MASLD substudy (Nature Medicine 2024)

The Phase 2a substudy by Sanyal and colleagues enrolled 98 participants from the parent obesity trial with elevated liver fat by MRI-PDFF (≥10% at baseline) ^[4]. At 48 weeks the 12 mg arm reduced liver fat by 86.0% relative to baseline, versus 4.6% on placebo. Roughly 90% of participants with baseline MASLD achieved resolution of hepatic steatosis (PDFF <5%). No hepatotoxicity signals were identified through 48 weeks. The magnitude of the liver-fat effect is the largest yet reported in a controlled pharmacotherapy trial — likely reflecting the GCGR contribution to hepatic fat oxidation.

TRIUMPH Phase 3 program

The TRIUMPH program is the Phase 3 development plan for retatrutide. It comprises at least five trials spanning general obesity, type 2 diabetes, established cardiovascular disease, obesity with knee osteoarthritis, and obstructive sleep apnea.

TRIUMPH-4 (NCT05931367) was the first to read out, in December 2025. In 445 adults with obesity and symptomatic knee osteoarthritis randomized over 68 weeks, mean body-weight reductions were -26.4% on the 9 mg arm and -28.7% on the 12 mg arm versus -2.1% on placebo, plus a 75.8% reduction in the WOMAC pain subscale; 12–14% of treated participants were pain-free at week 68 versus 4.2% on placebo ^[8].

TRIUMPH-1 (NCT05929066), the pivotal 80-week obesity trial in adults without type 2 diabetes, is the readout most analogous to the SURMOUNT-1 and STEP-1 trials of the existing approved incretin agonists ^[11]. Primary readout is anticipated in 2026. TRIUMPH-3 (NCT05882045) is the cardiovascular outcomes trial in adults with obesity and established cardiovascular disease — the readout that will characterize the major adverse cardiovascular events (MACE) signal and that, historically, has been required for full obesity-indication approval at scale ^[12].

Other 2024–2025 reports

A 2025 preclinical study in murine models reported that retatrutide attenuated tumor progression in obesity-associated pancreatic and lung adenocarcinoma ^[13]. The finding is hypothesis-generating and not a human cancer indication. A 2025 review in Biomolecules synthesized the receptor pharmacology, Phase 1–2 efficacy and safety, and Phase 3 program design — useful as a single-document overview ^[15].

What the literature does not yet establish

It is worth being explicit about what the published literature does not yet answer.

Long-term cardiovascular outcomes are not established. TRIUMPH-3, the dedicated cardiovascular outcomes trial, is the readout that will characterize the major adverse cardiovascular event signal in adults with obesity and established cardiovascular disease ^[12]. Until that readout, the dose-dependent transient rise in resting heart rate observed in Phase 2 ^[10] is a finding to track, not a finding to dismiss.

Durability of weight loss beyond 48 weeks in the general obesity population is not established. The 80-week TRIUMPH-1 readout will be the first published data point beyond the Phase 2 horizon ^[11]. Whether the linear dose-response observed at 24 and 48 weeks continues to extend or whether a plateau eventually appears is exactly the kind of question that requires a longer trial to answer.

Lean-mass preservation is partially answered by the 2025 body-composition substudy ^[14], which reported favorable fat-to-lean ratios across the dose cohorts, but the substudy was nested in the Phase 2 type 2 diabetes trial and the question is open in broader populations.

Finally, the long-term hepatic and pancreatic safety profile in broad populations requires the full Phase 3 program. The 48-week MASLD substudy is encouraging on hepatotoxicity ^[4], and the body-composition data are encouraging on lean mass, but neither is a substitute for the Phase 3 dataset that the regulatory review will ultimately rest on.